Albuterol+Budesonide 90mcg+80mcg Suppliers & Bulk Manufacturers

Available Forms: Inhalation

Available Strengths: 90mcg+80mcg

Reference Brands: Airsupra (USA)

Category: Respiratory Disorder

Albuterol/Budesonide is a combination inhaler used to manage and prevent asthma and other chronic respiratory conditions. Albuterol is a short-acting β₂-agonist (SABA) that provides quick relief from bronchospasm by relaxing the airway muscles, while Budesonide is an inhaled corticosteroid (ICS) that reduces airway inflammation and prevents asthma attacks. This combination can be used as-needed for immediate relief (in products like Airsupra) or as maintenance therapy (in products like Symbicort or DuoResp) depending on the formulation. It helps improve breathing, reduce wheezing, and lower the frequency of asthma exacerbations.

Product Description:

This fixed combination of albuterol with budesonide represents a genuine change in asthma treatment strategy rather than a convenience formulation. Conventional practice pairs a short-acting beta-2 agonist used as needed for symptoms with a separately dosed inhaled corticosteroid taken regularly. The difficulty is that patients reliably take the reliever, which produces immediate relief, and unreliably take the controller, which does not.

Combining the two in a single rescue inhaler means every time a patient treats symptoms they also receive an anti-inflammatory dose — an "anti-inflammatory reliever" approach. It is indicated to reduce the risk of exacerbations in asthma.

Sourcing notes. This is a recent, on-patent innovator product. It is not generically available and cannot be quoted as a generic; enquiries seeking bulk supply are, in practice, enquiries for the branded product through authorised distribution. Where the underlying requirement is inhaled corticosteroid plus reliever therapy, the established option is separate albuterol and budesonide inhalers, both widely genericised and readily sourced, or a conventional ICS/LABA combination. That is usually the workable answer to this enquiry. Manufacture in any case requires pressurised metered-dose inhaler capability with combination-product dose uniformity validation, which is held by a small number of sites globally.